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To the editors, 
 
We read the review on clozapine-induced gastrointestinal hypomotility (CIGH) 
by West et al. 1 with interest and welcome the further highlighting of this adverse 
effect spectrum. However, the authors’ use of the term CIGH is misleading and 
the recommendation to withdraw clozapine in people with CIGH may seriously 
disadvantage people experiencing treatment-resistant schizophrenia. 
 
The authors define CIGH as “a paralytic ileus leading to a clinical condition 
similar to bowel obstruction”. However, the term CIGH was coined in 20082  and 
refers to the effects of clozapine in slowing transit throughout the 
gastrointestinal tract.3-7  Clozapine impairs gut motility dramatically and this 
may result in an array of clinical presentations, from mild constipation and 
delayed gastric emptying at one end, to paralytic ileus, toxic megacolon and 
possibly death at the other.  In other words, paralytic ileus and other life-
threatening complications of CIGH, conditions that necessitate urgent medical 
and possibly surgical intervention, are but a small sub-set of the CIGH spectrum 
 
Mild to moderate CIGH is very common, probably occurring in most people 
taking clozapine. Radiopaque marker studies show that 50-80% of clozapine-
treated patients have significant gastrointestinal hypomotility,3,4 with one study 
finding a median colonic transit time of 104.5 hours for clozapine-treated 
patients, > 4 times normative values.4 A recent systematic review found 
constipation prevalence rates of least 30% in clozapine users.8  Severe 
complications of CIGH, such as ileus, are rare, with an estimated prevalence of 
around 0.4% of clozapine users,4 albeit with a high case-fatality rate.2 The 
apparently precipitate nature of severe CIGH may also result in sudden death 
without the underlying cause having been identified even at autopsy.6 
 
West et al recommend that “once CIGH has occurred clozapine should be halted”. 
Whilst prompt withdrawal of clozapine is mandatory if paralytic ileus or other 
severe complications of CIGH develop, it is inappropriate for mild to moderate 
CIGH, which responds to assertive monitoring and prophylactic laxative use (e.g. 
the Porirua Protocol).5 Clozapine is a superior antipsychotic for treatment-
resistant schizophrenia, significantly improving outcomes for many. An analysis 
of cause-specific mortality in 66,881 patients with schizophrenia found clozapine 
was associated with the lowest overall mortality risk (0.74; p<0.0001) compared 
with no medication or other antipsychotic use.9 Discontinuing clozapine is often 
followed by significant relapse, deterioration in functioning, re-hospitalisation, 
and increased rates of compulsory treatment (e.g. Atkinson et al, 2007).10  
Should West et al.’s recommendation of clozapine withdrawal in the presence of 
CIGH be taken literally then unnecessary relapse and net harm would follow for 
thousands of patients worldwide. 
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